Investigation of Pulmonary Complications Induced by Radiotherapy and Chemotherapy in Patients with Breast Cancer through Spirometry, CT Scan Imaging Patterns, and Clinical Criteria in a Six-Month Follow-Up

IF 0.4 Q4 ONCOLOGY
Maryam Bahador, M. H. Larizadeh, M. S. Fekri, A. Naghibzadeh-Tahami, M. Mohseni, Fateme Arabnejad
{"title":"Investigation of Pulmonary Complications Induced by Radiotherapy and Chemotherapy in Patients with Breast Cancer through Spirometry, CT Scan Imaging Patterns, and Clinical Criteria in a Six-Month Follow-Up","authors":"Maryam Bahador, M. H. Larizadeh, M. S. Fekri, A. Naghibzadeh-Tahami, M. Mohseni, Fateme Arabnejad","doi":"10.30476/MEJC.2021.88710.1490","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study was to determine pulmonary complications induced by radiotherapy and chemotherapy in patients with breast cancer in a six-month follow-up. \nMethod: 80 patients with breast cancer who were referred to the Radio-oncology Center in Kerman were included in the current cohort study. At the baseline, spirometry and lung scan were obtained and all the patients were asked about their respiratory symptoms. After designing the patient’s treatment, dose volume histogram data was extracted. All the tests were repeated six months after radiotherapy. The prevalence of pneumonitis and fibrosis in radiographs were determined clinically and the reduction in the values of pulmonary function test parameters was determined. \nResults: In 40% of the patients, pulmonary volume was reduced and in 10%, pulmonary fibrosis occurred. Regarding pulmonary function before and six months after radiotherapy, the results revealed that FeV1 (l/s) parameter decreased from 2.68 to 2.48 (P < 0.0001) six months after radiotherapy. FVC parameter also showed a decrease from 3.14 to 2.91 (P < 0.0001) in the same span of time. The odds of developing clinical symptoms in people with pulmonary fibrosis was five times higher than of those without this condition, (OR: 5.51, 95% CI: 1.10 - 27. 42), which was statistically significant (P = 0.03). None of the factors, including mean lung dose, tamoxifen, and age, affected Fev1 and pulmonary fibrosis. \nConclusion: Our results indicated that 10% of the patients undergoing treatment for breast cancer developed pulmonary fibrosis and 40% of the patients suffered from reduced pulmonary volumes, which was not associated with chemotherapy regimen or the use of tamoxifen.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2021-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30476/MEJC.2021.88710.1490","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The aim of this study was to determine pulmonary complications induced by radiotherapy and chemotherapy in patients with breast cancer in a six-month follow-up. Method: 80 patients with breast cancer who were referred to the Radio-oncology Center in Kerman were included in the current cohort study. At the baseline, spirometry and lung scan were obtained and all the patients were asked about their respiratory symptoms. After designing the patient’s treatment, dose volume histogram data was extracted. All the tests were repeated six months after radiotherapy. The prevalence of pneumonitis and fibrosis in radiographs were determined clinically and the reduction in the values of pulmonary function test parameters was determined. Results: In 40% of the patients, pulmonary volume was reduced and in 10%, pulmonary fibrosis occurred. Regarding pulmonary function before and six months after radiotherapy, the results revealed that FeV1 (l/s) parameter decreased from 2.68 to 2.48 (P < 0.0001) six months after radiotherapy. FVC parameter also showed a decrease from 3.14 to 2.91 (P < 0.0001) in the same span of time. The odds of developing clinical symptoms in people with pulmonary fibrosis was five times higher than of those without this condition, (OR: 5.51, 95% CI: 1.10 - 27. 42), which was statistically significant (P = 0.03). None of the factors, including mean lung dose, tamoxifen, and age, affected Fev1 and pulmonary fibrosis. Conclusion: Our results indicated that 10% of the patients undergoing treatment for breast cancer developed pulmonary fibrosis and 40% of the patients suffered from reduced pulmonary volumes, which was not associated with chemotherapy regimen or the use of tamoxifen.
随访6个月,通过肺量测定、CT扫描影像模式和临床标准探讨乳腺癌放化疗患者肺部并发症
背景:本研究的目的是确定癌症患者在6个月的随访中放疗和化疗引起的肺部并发症。方法:将80例转诊至克尔曼放射免疫中心的癌症患者纳入当前的队列研究。在基线时,进行肺活量测定和肺部扫描,并询问所有患者的呼吸道症状。在设计患者的治疗后,提取剂量-体积直方图数据。放射治疗后6个月重复进行所有检查。临床上确定了肺炎和纤维化在X线片中的患病率,并确定了肺功能测试参数值的降低。结果:40%的患者肺容量减少,10%的患者出现肺纤维化。关于放疗前和放疗后6个月的肺功能,结果显示,FeV1(l/s)参数在放疗后6月从2.68降至2.48(P<0.0001)。FVC参数在同一时间段内也从3.14下降到2.91(P<0.0001)。肺纤维化患者出现临床症状的几率是无肺纤维化患者的五倍(OR:5.51,95%CI:1.10-27)。42),具有统计学意义(P=0.03)。包括平均肺剂量、他莫昔芬和年龄在内的所有因素都不影响Fev1和肺纤维化。结论:我们的研究结果表明,接受癌症治疗的患者中有10%出现肺纤维化,40%的患者出现肺容量减少,这与化疗方案或他莫昔芬的使用无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊介绍: Middle East Journal of Cancer (MEJC) is an international peer-reviewed journal which aims to publish high-quality basic science and clinical research in the field of cancer. This journal will also reflect the current status of research as well as diagnostic and treatment practices in the field of cancer in the Middle East, where cancer is becoming a growing health problem. Lastly, MEJC would like to become a model for regional journals with an international outlook. Accordingly, manuscripts from authors anywhere in the world will be considered for publication. MEJC will be published on a quarterly basis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信